Brief: Galecto Provides Enrollment Update On Phase 2A Mylox-1 Trial And Reiterates Expected Timing Of Multiple Data Readouts In 2022

Damora Therapeutics

20/12/2021 13:25

Dec 20 (Reuters) - Galecto Inc  GLTO.O :
    * GALECTO PROVIDES ENROLLMENT UPDATE ON PHASE 2A MYLOX-1
TRIAL AND
REITERATES EXPECTED TIMING OF MULTIPLE DATA READOUTS IN 2022
    * GALECTO INC - ENROLLED 10 OF ANTICIPATED 16 PATIENTS IN
ITS
PHASE 2A TRIAL OF ITS ORAL LOXL2 INHIBITOR GB2064 IN
MYELOFIBROSIS
    * GALECTO INC - ALSO ANTICIPATE REPORTING TOPLINE DATA FROM
PART 2
OF OUR LIVER CIRRHOSIS GULLIVER-2 TRIAL NEXT YEAR

Source text for Eikon:  ID:nGNX5DFnqF 
Further company coverage:  GLTO.O 

 ((Reuters.Briefs@thomsonreuters.com;))